Sponsored
New Cyventine for smoking cessation
Cyventine™ (cytisine) is a new OTC way to help people (aged 18-65 years) quit smoking in 25 days.1 Cyventine is similar to varenicline, they are both partial agonists of the …
The first new smoking cessation aid registered in almost 20 years: a pharmacist’s guide to cytisine
George Krassas, Director and Medical Writer, Scius Healthcare Solutions Reviewed by Dr Brett MacFarlane Cytisine (Cyventine™) is the first new chemical entity registered in Australia to help people quit smoking …
Management of moderate–severe allergic rhinitis
Pharmacists can improve moderate–severe allergic rhinitis management by assessing symptom severity, matching treatment including dual therapy to patient needs, and reinforcing correct nasal spray technique. Shalini Jai Kumar BPharm (Hons), …
Cystic fibrosis management: an update on CFTR modulator therapy
CFTR modulator therapies have transformed cystic fibrosis care by improving the function of defective CFTR protein in people with responsive CFTR variants. Pharmacists should support safe and effective use of …
Allergic rhinitis relief starts with the right questions
Allergic rhinitis (AR) is often underdiagnosed and undermanaged.1,2 When patients present with allergy symptoms, a simple Spot it, Treat it, Check it approach can help guide the conversation. 1.Spot it …
New clinical apps provide trusted support across the medicines management journey
As every pharmacist knows, safe and effective medicines management relies on sound clinical decisions at every stage of patient care. From reviewing prescriptions and optimising therapy through to dispensing and …
Children’s Claratyne: clarity in kids’ hayfever
Allergic rhinitis a common condition with pervasive impacts on children. Allergic rhinitis (AR) or hayfever, is common, affecting up to 40% of children.1 AR and asthma commonly coexist, with AR …
Cyventine, the new, nicotine-free, pharmacist only smoking cessation therapy
Cyventine (cytisine) is the first new chemical entity registered in Australia to help adults (aged 18 to 65 years) quit smoking in almost two decades.1* Like varenicline, cytisine is a …
Small interactions, real impact: Building trust in opioid dependence care
An estimated 160,000 Australians are living with opioid dependence1. Whether they’re considering treatment or already receiving it, many face the challenges of a chronic health condition that remains misunderstood and …
Product news for September 2026
Switch to Poly Visc single pack From 1 August 2026, the Poly Visc Lubricating Eye Ointment Twin Pack has been discontinued. After this date, any remaining stock can continue to …
Beyond the runny nose: why allergic rhinitis management matters
Allergic rhinitis (AR) is the most common allergic condition in Australia, with almost 6.4 million cases reported in 2024.1 Yet despite its high prevalence, allergic rhinitis is often underdiagnosed and …
Chronic hand eczema: a pharmacist’s guide to novel therapy
Chronic hand eczema is a particularly challenging condition for patients who experience ongoing inflammation, itch and pain. Potent topical corticosteroids are often required to control flares, but chronic use may …